Scottish biotech ILC Therapeutics has set its sights on a Series A round and an IPO following its most recent investment round and is on track to commercialise a suite of antiviral medicines for the treatment of respiratory infections including

Scottish biotech ILC Therapeutics has signed a R&D partnership with international veterinary group Dechra Pharmaceuticals PLC  which will see both entities develop ILC’s Caniferon product to treat atopic dermatitis in dogs. Atopic dermatitis is the most common form of eczema affecting

• Drug also has potential to treat SARS, HIV, hepatitis and respiratory infection (RSV)• Earlier research shows drug is 15-20 times more potent than other interferons• Far fewer side effects than current treatments ILC Therapeutics has completed in vivo tests

A vacancy has arisen for the position of Quality Assurance Manager with ILC Therapeutics at BioCity. Summary The QA Manager shall be responsible for the implementation of the Quality Management System, working with colleagues to ensure compliance with the QMS

ILC Therapeutics is looking for a proactive and dedicated research associate or senior research associate (depending on the level of experience) who will be a key member of the scientific team. He or she must have validated laboratory skills in

Pioneering biotech company strengthened by senior appointments to bolster capabilities in research, product development and clinical trials of COVID-19 drug.  Company ready to accelerate the development of Alfacyte™ – ILC’s lead hybrid interferon designed to combat viral infections including COVID-19.

As we live through the most rapidly evolving viral environment the world has seen, there is a critical need for effective and safe antiviral medicines to meet the challenges of today and the inevitable threats of tomorrow. Worldwide, we are

ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of interferon drugs…

ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a new class of interferon drugs…

An interview with Founder & Chief Scientific Officer William Stimson in Drug Discovery World.

ILC Therapeutics has welcomed NHS plans to make Covid-19 treatments available to patients as soon as possible.

ILC Therapeutics has secured substantial funding from its first international investor, Medical Incubator Japan (MIJ).

ILC Therapeutics has confirmed that its unique synthetic Interferon called Alfacyte™ is 15 to 20 times more effective at preventing the spread of SARS-CoV-2 Independent research at the University of St Andrews demonstrated the superior effectiveness of Alfacyte™ in vitro

ILC Therapeutics has struck a research partnership with the University of St Andrews in a bid to progress a therapeutic drug which can treat COVID-19 towards clinical trials.